肿瘤细胞治疗研究
英文原题：BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.
我们的结果提示可使用 BCMA CAR-T 和新型靶向药物。
尽管布鲁顿酪氨酸激酶抑制剂靶向治疗显著改善了慢性淋巴细胞白血病（CLL）预后，创新疗法时代仍存在严重的Richter转化风险。我们报告一例罕见病例：一名61岁男性患者接受伊布替尼治疗后，CLL转化为同步发生、克隆相关的浆母细胞淋巴瘤（PBL）。新冠疫情期间，患者停用伊布替尼，导致病情加重。组织学检查显示，右锁骨上肿块内存在PBL，CLL已浸润骨髓。患者接受3个周期CHP（环磷酰胺、多柔比星和泼尼松）联合维奈克拉及维布妥昔单抗治疗。随后接受BCMA CAR-T细胞治疗，达到完全缓解。对于预后较差、治疗选择有限的PBL转化病例，我们的结果提示可考虑采用BCMA CAR-T及新型靶向药物。
Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton's tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old male patient's CLL transforming into a synchronous clonal related plasmablastic lymphoma (PBL) after receiving ibrutinib. During COVID-19, the patient stopped taking ibrutinib, which caused the illness to worsen. Histology revealed that PBL was present in the right supraclavicular mass and that CLL had penetrated the bone marrow. Three cycles of CHP (cyclophosphamide, doxorubicin, and prednisone) were administered together with venetoclax and brentuximab vedotin. After receiving BCMA CAR-T cell treatment, the patient was in complete remission. For PBL transformation, a condition with a worse prognosis and few therapy choices, our results suggest the use of BCMA CAR-T and novel target agents.
MEMBER ACCOUNT
登录成功会直接打开下一页。
